What is Synageva BioPharma Cyclically Adjusted Revenue per Share?
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
Synageva BioPharma's adjusted revenue per share for the three months ended in Mar. 2015 was €0.023. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.00 for the trailing ten years ended in Mar. 2015.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.
As of today (2024-06-10), Synageva BioPharma's current stock price is €211.31. Synageva BioPharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2015 was €0.00. Synageva BioPharma's Cyclically Adjusted PS Ratio of today is .
Synageva BioPharma Cyclically Adjusted Revenue per Share Historical Data
The historical data trend for Synageva BioPharma's Cyclically Adjusted Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synageva BioPharma Cyclically Adjusted Revenue per Share Chart
|
Synageva BioPharma Annual Data
|
|
Trend |
Dec05 |
Dec06 |
Dec07 |
Dec08 |
Dec09 |
Dec10 |
Dec11 |
Dec12 |
Dec13 |
Dec14 |
| Cyclically Adjusted Revenue per Share |
|
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
- |
- |
|
Synageva BioPharma Quarterly Data
|
|
Jun10 |
Sep10 |
Dec10 |
Mar11 |
Jun11 |
Sep11 |
Dec11 |
Mar12 |
Jun12 |
Sep12 |
Dec12 |
Mar13 |
Jun13 |
Sep13 |
Dec13 |
Mar14 |
Jun14 |
Sep14 |
Dec14 |
Mar15 |
| Cyclically Adjusted Revenue per Share |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Synageva BioPharma's Cyclically Adjusted Revenue per Share
For the Biotechnology subindustry, Synageva BioPharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synageva BioPharma's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Synageva BioPharma's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Synageva BioPharma's Cyclically Adjusted PS Ratio falls into.
Synageva BioPharma Cyclically Adjusted Revenue per Share Calculation
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?
Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.
We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Synageva BioPharma's adjusted Revenue per Share data for the three months ended in Mar. 2015 was:
| Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2015 (Change) | * | Current CPI (Mar. 2015) |
| = | 0.023 | / | 99.6211 | * | 99.6211 |
| = | 0.023 |
Current CPI (Mar. 2015) = 99.6211.
Synageva BioPharma Quarterly Data
|
Revenue per Share |
CPI |
Adj_RevenuePerShare |
| 200506 |
0.831 |
82.062 |
1.009 |
| 200509 |
0.435 |
83.876 |
0.517 |
| 200512 |
0.567 |
83.032 |
0.680 |
| 200603 |
1.412 |
84.298 |
1.669 |
| 200606 |
1.313 |
85.606 |
1.528 |
| 200609 |
1.737 |
85.606 |
2.021 |
| 200612 |
-1.590 |
85.142 |
-1.860 |
| 200703 |
2.975 |
86.640 |
3.421 |
| 200706 |
1.529 |
87.906 |
1.733 |
| 200709 |
1.686 |
87.964 |
1.909 |
| 200712 |
1.934 |
88.616 |
2.174 |
| 200803 |
0.809 |
90.090 |
0.895 |
| 200806 |
0.685 |
92.320 |
0.739 |
| 200809 |
0.845 |
92.307 |
0.912 |
| 200812 |
0.650 |
88.697 |
0.730 |
| 200903 |
0.771 |
89.744 |
0.856 |
| 200906 |
0.579 |
91.003 |
0.634 |
| 200909 |
0.601 |
91.120 |
0.657 |
| 200912 |
0.488 |
91.111 |
0.534 |
| 201003 |
0.517 |
91.821 |
0.561 |
| 201006 |
0.597 |
91.962 |
0.647 |
| 201009 |
2.963 |
92.162 |
3.203 |
| 201012 |
-3.919 |
92.474 |
-4.222 |
| 201103 |
0.772 |
94.283 |
0.816 |
| 201106 |
2.243 |
95.235 |
2.346 |
| 201109 |
1.811 |
95.727 |
1.885 |
| 201112 |
0.107 |
95.213 |
0.112 |
| 201203 |
0.087 |
96.783 |
0.090 |
| 201206 |
0.084 |
96.819 |
0.086 |
| 201209 |
0.177 |
97.633 |
0.181 |
| 201212 |
0.153 |
96.871 |
0.157 |
| 201303 |
0.147 |
98.209 |
0.149 |
| 201306 |
0.095 |
98.518 |
0.096 |
| 201309 |
0.037 |
98.790 |
0.037 |
| 201312 |
0.082 |
98.326 |
0.083 |
| 201403 |
0.037 |
99.695 |
0.037 |
| 201406 |
0.052 |
100.560 |
0.052 |
| 201409 |
0.031 |
100.428 |
0.031 |
| 201412 |
0.030 |
99.070 |
0.030 |
| 201503 |
0.023 |
99.621 |
0.023 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Synageva BioPharma (FRA:TMS1) Business Description
Traded in Other Exchanges
N/A
Address
Synageva BioPharma Corp is incorporated in Delaware in 1993. On November 2, 2011, Trimeris, Inc., a Delaware corporation closed a merger transaction, Reverse Merger with Synageva BioPharma Corp., Pursuant to the Merger Agreement, Private Synageva became a wholly owned subsidiary of Trimeris. As a Reverse Merger, Trimeris changed its name to Synageva BioPharma Corp. The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The Company has several proteins therapeutic in its pipeline, including enzyme replacement therapies for lysosomal storage diseases (LSDs) and protein therapeutic programs for other rare diseases that are at the stage of preclinical development. Its program, sebelipase alfa is a recombinant human lysosomal acid lipase deficiency (LAL Deficiency), currently evaluating in global Phase 3 clinical trials in infants, children and adults with LAL Deficiency. LAL Deficiency is rare autosomal recessive LSD characterized by decreased LAL enzyme activity leading to intracellular accumulation of lipids. This disease leads to medical complications with significant morbidity and early mortality. Sebelipase alfa has been granted orphan designation by the FDA, the EMA, and the Japanese Ministry of Health, Labour and Welfare. Additionally, sebelipase alfa has received Fast Track Designation by the FDA, and Breakthrough Therapy designation by the FDA for LAL Deficiency presenting in infants. The Company has not yet received approval to market this product and is not currently commercializing any other products. Sebelipase alfa is a recombinant form of the human LAL enzyme under development as an enzyme replacement therapy for LAL Deficiency. The Company is currently enrolling and dosing Phase 3 Trial of Sebelipase Alfa in Children and Adults with LAL Deficiency. It is also pursuing a development strategy for sebelipase alfa to assess safety and tolerability in a broad population of patients, including infants, children, and adults, and to demonstrate efficacy, safety and tolerability of sebelipase alfa in the treatment of LAL Deficiency. Its potential competitors include large pharmaceutical and biotechnology companies and specialty pharmaceutical companies, academic institutions, government agencies, and research institutions. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its product candidates and future products, are subject to extensive regulation by governmental authorities in the U.S. and other countries.
Synageva BioPharma (FRA:TMS1) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:TMS1 has been successfully added to your